Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

St. Jude Medical Announces CE Mark Approval Of Ellipse ICD - Quick Facts

St. Jude Medical, Inc. (STJ: Quote) announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator, or ICD. ICDs are advanced implantable cardiac devices that treat potentially lethal, abnormally fast heart rhythms that often lead to sudden cardiac death.

According to the company, the Ellipse ICD provides the benefits of advanced features and power in the industry's smallest high-energy ICD.

Dr. L.R.C. Dekker, cardiologist from the Cardiac Center of the Catharina Hospital in Eindhoven, The Netherlands, who implanted the first Ellipse ICD in Europe, said, "Its thinness, longevity and new discrimination algorithms constitute the answers to the three main concerns of patients and their doctors: decreasing the volume of the can, reducing the risk for infection during ICD replacement and minimizing inappropriate shock."

Click here to receive FREE breaking news email alerts for St. Jude Medical Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The United Nations Security Council (UNSC) on Thursday declared the ongoing Ebola outbreak in West Africa "a threat to international peace and security." Notably, the declaration was made in the Council's first emergency meeting on a public health issue. The fifteen-member Council also unanimously... Oracle Corp. said Thursday after the markets closed that its first quarter profit fell slightly from last year, hurt mainly by higher income tax expenses even as revenue increased 3%. The company's quarterly earnings per share, excluding items, also came in below analysts' expectations as did its quarterly revenue. After ending the previous session mostly higher following the Federal Reserve's monetary policy announcement, stocks saw further upside during trading on Thursday. The gains on the day lifted the Dow and the S&P 500 to new record closing highs.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.